--- title: 'Regulatory Daily Summary: What Happened on November 5, 2026' headline: China clears Bayer’s sevabertinib for first-line lung cancer description: The decision rests on early study results. NICE also backed a bladder cancer combination. url: https://thebench.bio/news/regulatory/2026-11-05 topic: regulatory date: '2026-11-05' covers: - '2026-11-05' date_published: '2026-11-05T12:10:12Z' date_modified: '2026-11-05T12:10:12Z' tags: - Industry sources: 2 publisher: TheBench.Bio --- # Regulatory Daily Summary: What Happened on November 5, 2026 **China clears Bayer’s sevabertinib for first-line lung cancer** The decision rests on early study results. NICE also backed a bladder cancer combination. ## Today in brief China approved Bayer’s sevabertinib for adults with advanced HER2-mutated lung cancer who have not received prior treatment. [1] The approval relied on results from 73 patients, 75% of whom had tumors shrink. NICE also backed Keytruda with Padcev for bladder cancer. [1] [2] ## China extends sevabertinib to untreated HER2-mutated lung cancer China’s National Medical Products Administration approved Bayer’s sevabertinib for previously untreated adults with unresectable, locally advanced or metastatic non-small cell lung cancer with activating HER2 mutations. [1] The approval drew on 73 previously untreated patients in the ongoing Phase 1/2 SOHO-01 study. [1] In that cohort, 75% of patients had an objective response, meaning their tumors shrank. Six percent had a complete response and 70% had a partial response. [1] Among responders, 73% maintained their response for at least six months. [1] The early results do not establish whether sevabertinib improves progression-free or overall survival compared with standard care. [1] The FDA granted the drug accelerated first-line approval in September 2026. Japan authorized it for first-line use in August. [1] The ongoing Phase 3 SOHO-02 trial is comparing sevabertinib with standard therapy in previously untreated patients. [1] China authorized Boehringer Ingelheim’s zongertinib for first-line use in May 2026. Response rates from the two drugs’ studies should not be compared directly because the patients and follow-up differ. [1] ## Also worth knowing - NICE backed Keytruda and Padcev for bladder cancer. [2] ## The day in numbers - **73 patients**: Previously untreated patients in the SOHO-01 cohort supporting China’s approval. [1] - **75%**: Share of patients in the cohort whose tumors had an objective response. [1] ## Also published - [STAT+: In China, a flood of controversial clinical trials slows to a trickle ](), STAT Biotech - [The Citizen Petition That Reads Like Legislative History: ROS1/RET Meets the Precision Oncology Modernization Act](), FDA Law Blog ## Sources 1. [Bayer closes the gap with Boehringer in China’s lung cancer race](), European Biotechnology, 2026-11-05 2. [NICE backs Keytruda/Padcev combo for bladder cancer](), pharmaphorum, 2026-11-05 --- TheBench.Bio wrote this from the reporting cited above, with a language model drafting and editing. [1]: [2]: